Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme.
1. The results of the administration of the nona-peptide inhibitor (SQ 20,881) of the enzymatic conversion of angiotensin I into angiotensin II in twelve severe hypertensive patients are presented. 2. Administration of the compound was associated with a fall in blood pressure in ten of twelve patients. 3. Four patients had a normal plasma renin activity (PRA) with a range of 1.6-3.7 ng h-1 ml-1 and eight patients had a high PRA with a range of 5.0-74 ng h-1 ml-1. Two of the patients with normal PRA had no fall in blood pressure despite receiving 2 mg/kg of the compound. Two patients with normal PRA, however, did respond, thus indicating that a high PRA is not necessary for a response to the inhibitor compound. 4. It was found that haemodialysis or diuresis with frusemide enhanced the blood pressure response to the compound. 5. The presence of a measured low total blood volume was found to be associated with an exaggerated fall in blood pressure to a small dose of compound (0.125 mg/kg) in one patient.
D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume; D004305:Dose-Response Relationship, Drug; D005665:Furosemide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D013722:Teprotide / Q000627:therapeutic use*; D013997:Time Factors
D009842:Oligopeptides; D005665:Furosemide; D012964:Sodium; D013722:Teprotide; D012083:Renin